Thymosin Alpha 1 Reduces the Mortality of Severe Sepsis by Restoring Immunity
Liu F, Yin J, Du M, Yan P, Xu J, Zhu X, Fan J
Critical Care Medicine · Vol. 41(5) · pp. 1150–1159 · 2013
Randomized controlled trial demonstrating that Thymosin Alpha-1 significantly reduces 28-day mortality in severe sepsis patients by restoring T-cell immunity and reducing immune paralysis. One of the strongest clinical evidence papers for any peptide immunotherapy.
Key Findings
28-day mortality reduced from 35.2% to 26.0% with Tα1 treatment (p=0.027)
Tα1 restored HLA-DR expression on monocytes, reversing immune paralysis
Increased CD4+ T-cell counts and improved T-cell function in treated patients
Reduced secondary infections and organ failure in the treatment group
No significant adverse effects attributable to Tα1 treatment
Methodology
Prospective randomized controlled trial in ICU patients with severe sepsis. Primary endpoint: 28-day all-cause mortality. Secondary endpoints: immune markers, organ failure scores.
Limitations
Single-center study; larger multicenter replication needed. Patient population limited to severe sepsis — generalizability to other immune conditions unclear.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment